USA Financial Formulas Acquires 980 Shares of Regeneron Pharmaceuticals, Inc. $REGN

USA Financial Formulas bought a new position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor bought 980 shares of the biopharmaceutical company’s stock, valued at approximately $743,000.

Other hedge funds also recently added to or reduced their stakes in the company. New England Research & Management Inc. boosted its position in Regeneron Pharmaceuticals by 20.4% in the 3rd quarter. New England Research & Management Inc. now owns 4,185 shares of the biopharmaceutical company’s stock valued at $3,173,000 after buying an additional 710 shares during the period. Aspiriant LLC grew its stake in shares of Regeneron Pharmaceuticals by 12.7% in the third quarter. Aspiriant LLC now owns 524 shares of the biopharmaceutical company’s stock worth $397,000 after acquiring an additional 59 shares in the last quarter. Milestone Asset Management LLC acquired a new position in shares of Regeneron Pharmaceuticals in the third quarter worth $1,252,000. Activest Wealth Management increased its position in shares of Regeneron Pharmaceuticals by 780.0% during the third quarter. Activest Wealth Management now owns 44 shares of the biopharmaceutical company’s stock worth $33,000 after acquiring an additional 39 shares during the period. Finally, Purus Wealth Management LLC purchased a new stake in shares of Regeneron Pharmaceuticals during the third quarter worth $235,000. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Key Stories Impacting Regeneron Pharmaceuticals

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Strong quarterly performance supported the bullish case. Regeneron reported second-quarter revenue of $4.29 billion, up 16.7% year over year and above analyst expectations. Earnings per share of $14.29 also exceeded the $10.16 consensus estimate, reinforcing confidence in the company’s earnings momentum. Regeneron earnings and investment narrative
• Positive Sentiment: Positive 84-week Phase 3 OPTIMA data for Pasatru in adults with fibrodysplasia ossificans progressiva indicated a sustained reduction in new heterotopic bone lesions and disease flare-ups, with a generally consistent safety profile. The results could strengthen confidence in the treatment’s commercial opportunity. Regeneron OPTIMA trial results
• Positive Sentiment: UBS upgraded REGN to Buy and raised its price target to $978 from $660, citing greater long-term potential for Dupixent and arguing that the market may be undervaluing the business. UBS Regeneron upgrade
• Positive Sentiment: Libtayo received a positive recommendation from the European Medicines Agency’s CHMP for a dosing regimen that could reduce administration frequency from every three weeks to every six weeks after the first 12 weeks, potentially improving convenience and market appeal. Final EU approval is still required. Libtayo CHMP recommendation
• Negative Sentiment: Insider Andrew Murphy sold 4,147 shares worth approximately $3.2 million. The transaction was made under a pre-arranged Rule 10b5-1 plan, limiting its significance, but it may contribute modestly to near-term caution. Regeneron insider sale filing

Analysts Set New Price Targets

Several analysts have recently issued reports on REGN shares. JPMorgan Chase & Co. increased their price objective on Regeneron Pharmaceuticals from $900.00 to $950.00 and gave the company an “overweight” rating in a research note on Tuesday, October 6th. Cantor Fitzgerald lifted their target price on Regeneron Pharmaceuticals from $750.00 to $795.00 and gave the company an “overweight” rating in a report on Friday, July 31st. Sanford C. Bernstein boosted their target price on Regeneron Pharmaceuticals from $753.00 to $756.00 and gave the stock a “market perform” rating in a research note on Friday, August 14th. Jefferies Financial Group boosted their target price on Regeneron Pharmaceuticals from $870.00 to $930.00 and gave the stock a “buy” rating in a research note on Thursday, October 1st. Finally, Truist Financial upped their price target on Regeneron Pharmaceuticals from $772.00 to $780.00 and gave the stock a “buy” rating in a report on Wednesday, October 7th. One analyst has rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and eight have issued a Hold rating to the stock. Based on data from MarketBeat.com, Regeneron Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average target price of $845.21.

Insider Activity

In related news, insider Andrew J. Murphy sold 4,147 shares of the stock in a transaction on Wednesday, October 14th. The stock was sold at an average price of $772.70, for a total value of $3,204,386.90. Following the transaction, the insider owned 47,833 shares of the company’s stock, valued at $36,960,559.10. This represents a 7.98% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Kathryn Guarini sold 400 shares of the firm’s stock in a transaction on Wednesday, September 2nd. The shares were sold at an average price of $850.00, for a total value of $340,000.00. Following the completion of the sale, the director owned 603 shares in the company, valued at approximately $512,550. This represents a 39.88% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 8,093 shares of company stock valued at $6,506,845 in the last 90 days. Company insiders own 6.97% of the company’s stock.

Regeneron Pharmaceuticals Stock Down 0.7%

Shares of Regeneron Pharmaceuticals stock opened at $790.74 on Friday. The company has a quick ratio of 2.78, a current ratio of 3.34 and a debt-to-equity ratio of 0.06. Regeneron Pharmaceuticals, Inc. has a 52-week low of $566.11 and a 52-week high of $859.34. The company has a market capitalization of $81.41 billion, a P/E ratio of 19.54, a P/E/G ratio of 1.37 and a beta of 0.16. The company has a 50 day moving average of $791.72 and a 200 day moving average of $721.78.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $14.29 EPS for the quarter, topping the consensus estimate of $10.16 by $4.13. Regeneron Pharmaceuticals had a net margin of 27.86% and a return on equity of 13.47%. The company had revenue of $4.29 billion during the quarter, compared to analysts’ expectations of $3.82 billion. During the same quarter in the previous year, the business posted $12.81 EPS. The firm’s revenue was up 16.7% on a year-over-year basis. As a group, research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 47.93 EPS for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Monday, August 31st. Stockholders of record on Tuesday, August 18th were given a dividend of $0.94 per share. This represents a $3.76 annualized dividend and a dividend yield of 0.5%. The ex-dividend date of this dividend was Tuesday, August 18th. Regeneron Pharmaceuticals’s payout ratio is 9.29%.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc is a biotechnology company that discovers, develops and commercializes medicines for serious medical conditions. The company uses genetic and antibody-based research technologies to develop treatments in areas including eye diseases, allergic and inflammatory conditions, cancer, cardiovascular disease, infectious diseases and rare disorders.

Its marketed products include Eylea and Eylea HD for retinal diseases, Dupixent for several inflammatory and allergic conditions, Libtayo for certain cancers, Praluent for cardiovascular disease, Kevzara for rheumatoid arthritis, and other medicines such as Inmazeb, Evkeeza, Veopoz and Arcalyst.